

# THE AMERICAN JOURNAL OF MANAGED CARE®

## Publishing Staff

Senior Vice President  
of Operations and Clinical Affairs  
**Jeff D. Prescott, PharmD, RPh**

Senior Clinical Projects Manager  
**Ida Delmendo**

Clinical Projects Manager  
**Cindy Spielvogel**

Project Director  
**Christina Doong**

Quality Assurance Editor  
**David Allikas**

Associate Editor  
**Jeanne Linke**

Clinical Editor  
**Michael R. Page, PharmD, RPh**

Designer  
**Julianne Costello**

Associate Publisher  
**Justin T. Gallagher**

Director of Sales  
**Sara Stewart**

National Account Managers  
**Gabrielle Consola**  
**Michael Costella**

## Corporate

Chairman and CEO  
**Mike Hennessy, Sr**

Vice Chairman  
**Jack Lepping**

Executive Vice President,  
Mergers and Acquisitions  
**Tighe Blazier**

Chief Operating Officer  
**Neil Glasser, CPA/CFE**

President, Managed Markets  
**Brian Haug**

Executive Vice President  
and General Manager  
**John Maglione**

Vice President of Human Resources  
**Rich Weisman**

Chief Creative Officer  
**Jeff Brown**

Vice President of Education  
**David Heckard**

Copyright © 2015 by Managed Care  
& Healthcare Communications, LLC

August 2015 – Vol. 21, No. 9a, Sup.

## Use of Opioid Analgesics in Managed Care Practice: Challenges, Controversies, REMS, and Optimizing Patient Management

### Table of Contents

#### Participating Faculty

S166a

#### Reports

- The Continued Rise of Opioid Misuse: Opioid Use Disorder S169a

**Bill McCarberg, MD, FABPM**

- Implications of the Extended-Release/Long-Acting Opioid  
REMS for Managed Care S177a

**James B. Ray, PharmD, CPE**

- The Economics of Opioids: Abuse, REMS, and Treatment  
Benefits S188a

**Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP**

#### CE/CME Sample Posttest

S195a



# MH

A Supplement to *The American Journal of Managed Care*

www.ajmc.com

PROJ ACE029

# Use of Opioid Analgesics in Managed Care Practice: Challenges, Controversies, REMS, and Optimizing Patient Management

**Release date:** August 15, 2015

**Expiration date:** August 15, 2016

**Estimated time to complete activity:** 3.0 hours

**Type of activity:** Knowledge

**Medium:** Print with Internet-based posttest, evaluation, and request for credit

**Fee:** Free

This activity has been supported through independent educational grants from Purdue Pharma LP and Teva Pharmaceuticals.

## Intended Audience

Managed care physicians and pharmacists.

## Activity Overview

The management of chronic pain can be complex, and it frequently presents itself as a multidimensional problem that seriously impacts both the culture and economy of managed care practice. Opioid analgesics available by prescription have been used for many years to treat acute medical, traumatic, and postoperative pain, along with chronic pain that frequently accompanies malignancies and end-stage illnesses. Beginning in the 1980s, the medical community moved to more widespread use of opioids for treatment of non-cancer pain, leading to the prescribing of considerable quantities of these drugs. This increase subsequently led to unintended consequences, including inappropriate self-medication by patients and recreational use of these drugs. While opioids are generally considered to be some of the most effective drugs for pain management, their use has become a critical public health concern due to abuse of these medications, addiction, and deaths from opioid overdose. Both immediate- and extended-release opioid formulations are abused and are known to have contributed to overdoses.

This supplement to *The American Journal of Managed Care* will describe patients with or at risk for opioid use disorder to facilitate early intervention and treatment, outline the clinical and economic impact of opioid misuse and the implementation of a Risk Evaluation and Mitigation Strategy (REMS) program into managed care practice, and distinguish between general and product-specific drug information surrounding different extended-release and long-acting opioid analgesics, including updated safety labeling.

## Statement of Educational Need

Opioids are thought to be the most effective drug for pain management, and their use has increased 10-fold since the 1990s. However, the use of opioids has created a major public health concern due to misuse and abuse. Opioid abuse generates increased costs for healthcare providers, payers, and society as a whole. It is important for healthcare providers to be aware of the substantial economic burden of opioid misuse, which has been estimated at \$53 billion annually in the United States. Opioid abusers utilize healthcare services 8 times more than non-abusers. In an attempt to ensure the safe prescribing of this class, the FDA has enacted a classwide REMS program that requires prescriber and patient education. Physicians are reluctant to prescribe opioids because of a lack of confidence in treating non-cancer-related pain, a fear of patient abuse, and the necessity of com-

plying with the REMS requirements. This could leave a substantial number of patients with legitimate chronic pain receiving inadequate pain management. In order to ensure the safe use of opioids, clinicians and payers must understand that the cost of implementing REMS elements offsets the cost of opioid abuse and must ensure that the REMS elements are integrated into standard practice. Prescribers must feel that the REMS elements are not a burden to their practice and will not impact patient care. In the end, this will help to ensure better identification of appropriate patients for opioid therapy and better pain management.

## Educational Objectives

Upon completion of this activity, participants should be able to:

- Review patients with or at risk for opioid use disorder to facilitate early intervention and treatment
- Outline the clinical and economic impact of opioid misuse and its effects on both patients and society at large
- Recall the clinical and economic impact of implementing a REMS program into managed care practice
- Discuss the general and product-specific drug information surrounding different extended-release/long-acting opioid analgesics, including updated safety labeling

## Physician Credit

### Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Pharmacy Times Office of Continuing Professional Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

### Credit Designation

The University of Cincinnati designates this journal-based activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Accreditation Statement



Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 3.0 contact hours (0.3 CEUs) under the ACPE universal activity number 0290-9999-15-094-H01-P. The activity is available for CE credit through August 15, 2016.

**Obtaining Credit:** Participants must read the article, complete the online posttest achieving a passing score of 70% or higher, and complete an online evaluation and request for credit. Detailed instructions on obtaining CE/CME credit are included at the end of this activity.

This CE activity is also offered free online at [www.arcmesa.org](http://www.arcmesa.org) and [www.ajmc.com/ce](http://www.ajmc.com/ce) (for AMA PRA Category 1™ credit) and at [www.PharmacyTimes.org](http://www.PharmacyTimes.org) (for CEUs), where you will be directed to the activity in its entirety, including the online pretest and posttest, activity evaluation, and request for credit.

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

## Use of Opioid Analgesics in Managed Care Practice: Challenges, Controversies, REMS, and Optimizing Patient Management

This supplement to *The American Journal of Managed Care* describes patients with or at risk for opioid use disorder to facilitate early intervention and treatment, outline the clinical and economic impact of opioid misuse and the implementation of a REMS program into managed care practice, and distinguish between general and product-specific drug information surrounding different extended-release and long-acting opioid analgesics, including updated safety labeling.

### ■ Faculty

#### **Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP**

Adjunct Associate Professor  
Western New England University  
College of Pharmacy  
Springfield, Massachusetts

Adjunct Assistant Professor of Pharmacy Practice  
University of Connecticut School of Pharmacy  
Storrs, Connecticut

Clinical Pharmacy Specialist in Pain Management  
Director  
PGY2 Pharmacy Pain & Palliative Care Residency  
Stratton VA Medical Center  
Albany, New York\*

#### **Bill McCarberg, MD, FABPM**

Physician  
Neighborhood Healthcare  
Medical Director  
Elizabeth Hospice  
Escondido, California

Adjunct Assistant Clinical Professor  
University of California San Diego

President  
American Academy of Pain Medicine

#### **James B. Ray, PharmD, CPE**

James A. Otterbeck OnePoint Patient Care  
Clinical Associate Professor in Hospice and Palliative Care  
Department of Pharmacy Practice and Science  
University of Iowa College of Pharmacy  
Iowa City, Iowa

### ■ Editorial Support

#### **Jill E. Allen, PharmD, BCPS**

Drug Information Consultant  
Pin Oak Associates  
Salt Lake City, Utah

#### **Priya Karkhanis, MS**

Scientific Consultant  
Hillsborough, New Jersey

#### **Christine Sokoloski, MS**

Scientific Consultant  
Hillsborough, New Jersey

\*Statements are the sole opinion of Dr. Fudin and do not reflect the opinion of employers, employee affiliates.

## ■ Faculty Disclosures

**Jeffrey Fudin, PharmD, DAAPM, FCCP, FASHP**, reports the following relevant commercial financial relationships in the past 12 months:

*Consultant:*

AstraZeneca, Depomed, Kaléo Pharma, Millennium Health LLC, Zogenix

*Speakers' bureaus:*

AstraZeneca, Kaléo Pharma, Millennium Health LLC

*Lecture fees:*

PainWeek and Pain Weekend

**Bill McCarberg, MD, FABPM**, reports the following relevant commercial financial relationships or affiliations in the past 12 months:

*Consultant:*

AstraZeneca, Collegium, Depomed, Inspirion, Iroko, Janssen, Kaléo, Mallinckrodt, Millennium, Pfizer, Salix, Takeda, Zogenix

*Board membership:*

American Academy of Pain Medicine, American Board of Pain Medicine

*Stockholder:*

Biospecifics Technologies, Galena, Johnson & Johnson, Nektar Therapeutics, Protein Design Labs

**James B. Ray, PharmD, CPE**, reports the following relevant commercial financial relationships or affiliations in the past 12 months:

*Consultant and honoraria:*

AstraZeneca, Mallinckrodt Pharmaceuticals

*Lecture fees:*

PainWeek and Pain Weekend

*Meeting/conference attendance:*

PainWeek

*Stockholder:*

Alchemy Consulting, PC

## ■ Editorial Support Disclosures

**Jill E. Allen, PharmD, BCPS; Priya Karkhanis, MS; and Christine Sokoloski, MS**, have no relevant commercial financial relationships or affiliations to disclose.

### ***The American Journal of Managed Care***

*Publishing Staff*—Jeff D. Prescott, PharmD, RPh; Ida Delmendo; and Cindy Spielvogel have no relevant financial relationships with commercial interests to disclose.

### **University of Cincinnati**

*Planning Staff*—Susan P. Tyler, MEd, CMP, CHCP, CME Director, University of Cincinnati, has nothing to disclose.

*CME Physician Reviewer*—Rick Ricer, MD, University of Cincinnati, has nothing to disclose.

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Plainsboro, New Jersey.

## ■ Editorial Support Disclosures (Continued)

### Pharmacy Times Office of Continuing Professional Education

*Planning Staff*—David Heckard; Maryjo Dixon, RPh; Donna Fausak; and Nathalie Harden have no relevant financial relationships with commercial interests to disclose.

## ■ Disclosure Policy

According to the disclosure policy of the University of Cincinnati, all persons who are in a position to control content are required to disclose any relevant financial relationships with commercial interests. If a conflict is identified, it is the responsibility of the University of Cincinnati and Pharmacy Times Office of Continuing Professional Education to initiate a mechanism to resolve the conflict(s). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

## ■ Disclosure of Unapproved/Off-Label Use

The contents of this activity may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Participants should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.

The information provided in this CE/CME activity is for continuing medical and pharmacy education purposes only and is not meant to substitute for the independent medical or pharmacy judgment of a physician or pharmacist relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of *The American Journal of Managed Care*, Pharmacy Times Office of Continuing Professional Education, the University of Cincinnati, or any of the companies that provided commercial support for this CE/CME activity.

## ■ SUPPLEMENT POLICY STATEMENT ■

### Standards for Supplements to *The American Journal of Managed Care*

All supplements to *The American Journal of Managed Care* are designed to facilitate and enhance ongoing medical education in various therapeutic disciplines. All *Journal* supplements adhere to standards of fairness and objectivity, as outlined below. Supplements to *The American Journal of Managed Care* will:

- I. Be reviewed by at least one independent expert from a recognized academic medical institution.
- II. Disclose the source of funding in at least one prominent place.
- III. Disclose any existence of financial interests of supplement contributors to the funding organization.
- IV. Use generic drug names only, except as needed to differentiate between therapies of similar class and indication.
- V. Be up-to-date, reflecting the current (as of date of publication) standard of care.
- VI. Be visually distinct from *The American Journal of Managed Care*.
- VII. Publish information that is substantially different in form and content from that of the accompanying edition of *The American Journal of Managed Care*.
- VIII. Prohibit excessive remuneration for contributors and reviewers.
- IX. Carry no advertising.

**Publisher's Note:** The opinions expressed in this supplement are those of the authors, presenters, and/or panelists and are not attributable to the sponsor or the publisher, editor, or editorial board of *The American Journal of Managed Care*. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this supplement are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience of the authors, presenters, and/or panelists or may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.